
Diagnostic Services
Explore our wide range of services. Personalized diagnostics for better health.

Newborn Screening
Screening of the Next Generation. Complete neonatal diagnostic programs incl. confirmatory and differential diagnostics.

Dried Blood Spots
From Biochemical testing incl. Biomarkers and Next-Generation Sequencing.
Laboratory Services
Rare Disease and Specialty Diagnostics
Rare Disease and Specialty Diagnostics
One Rare Disease may affect only a handful of patients, and another may touch thousands. More than 30 million people are affected.
50% of Rare Diseases affect children.
Our diagnostic services help to improve diagnosis, chance for treatment and to help families, including their children, obtain a fast and reliable diagnosis.
Visit our Rare Disease webpages to learn more about our diagnostic services focused on Rare Diseases.
Premium diagnostic services delivering reliable results for Rare Disease diagnosis using advanced analytical techniques including enzyme, biomarker, and genetic testing.
Explore our diagnostic activities in:
Biotech and Pharma
Biotech and Pharma
International Diagnostic Services
We support pharmaceutical and biotech companies in performing comprehensive (international) diagnostic services particularly in the area of rare disorders and once novel treatments are available, to raise disease awareness across borders.
We offer the set-up of all relevant processes and infrastructure from logistics, legal and marketing, to comprehensive laboratory analysis and medical reporting. Fast, reliable and high-quality services combined with cutting-edge laboratory technologies from Clinical Mass Spectrometry to Next-Generation Sequencing.
Biomarker Discovery and Testing
Every day we learn more and more on the nature of diseases. We work hand in hand with international medical and scientific experts in the discovery of new supportive biomarkers or improve existing laboratory tests using innovative technologies. Our experts in the research division are working in several global projects on the identification and evaluation of novel biomarkers in different medical fields with cutting edge technologies.
Our goal is to make biomarkers accessible for patients. Physicians and their patients shall benefit from additional supportive biomarkers for better diagnosis and/or disease monitoring. ARCHIMEDlife´s Dual Strategy is to develop biomarker tests that can be used for diagnostic purposes. Beneficial biomarker tests shall not stay on a research level. Our Development Division (ISO 13485 certified) has all requirements and expertise to validate and certify biomarker tests to make them accessible for patients in a daily routine laboratory.
Development and Certification of Novel Diagnostic Assays
Novel biomarker or an innovative diagnostic test on the horizon but still on “research use only” (RUO) level and not validated?
Our Development Division is fully ISO 13485 certified, and we have all necessary regulatory and legal processes in place to validate, certify, register and release any diagnostic assay for the in-vitro diagnostic (IVD) market, or use it in our highly-specialized clinical routine laboratories for your diagnostic project.
The diagnostic market is changing with personalized medicine and novel treatments that become available for e.g. rare disorders or in oncology. So, innovative and better diagnostic assays are needed to characterize patients and their disease, or to monitor progression of disease without or under treatment.
Diagnostic Support in Clinical Studies
We offer hiqh-quality services with our strong experience for Clinical Studies and Academic Research.
Our team is well experienced in both biochemistry and genetics applied in medical studies and research projects. Our laboratory is equipped with state-of-the-art technologies from Clinical Mass Spectrometry to Next-Generation Sequencing including qualified instruments, and our highly-experienced team will support you from planning to execution of your study.
We provide clinical services including:
- Sample management
- Pre-analytical sample work-up and processing
- Assay development and validation
- Development of quality control materials and quantification strategies
- Qualitative and quantitative measurement of metabolites, proteins using Clinical Mass Spectrometry, Immunoassays or cell and bead-based flow cytometry
- Genetic testing from Sanger to Next-Generation Sequencing (NGS) including whole-exome sequencing (WES) and whole-genome sequencing (WGS)
- Support in bioinformatic and statistical data analysis
Research and Clinical Trial Support
Research and Clinical Trial Support
Academic Research
We are your industrial partner with a highly experienced team and laboratory instruments for your academic research activities. We have started ARCHIMEDlife Research Institute as an initiative for “bench to bedside” medical research. We combine several strategies in translational research to advance progress from laboratory discovery to application, and final access for patients. A research process involves clinicians and researchers working together to solve health challenges faster.
Apply for a research grant? Increase your chance by collaborating with us – a service partner with a highly experienced research team and cutting-edge technologies. We have conduced successfully dozens of studies, and supported research teams worldwide with analytical services.
Several translational research projects are underway at ARCHIMEDlife Research Institute, including:
- Biomarker research for Lysosomal Storage Disorders and others for Rare Disorders
- Hemoglobinopathies – Better characterization using HR/MS
- Metabolites involved in oncology
- Optimizing the work with small sample volumes and multiplexing different technologies to avoid subsequent blood sampling for confirmatory and follow-up testing
Metabolic Research
We have several Mass Spectrometry instruments (e.g. SCIEX 6500 QQQ, Thermo Fischer Scientific Orbitrap TM) for quantification of small molecules and discovery of novel biomarkers.
Genetic Research
We are highly experienced in the development of novel genetic tests using state-of-the-art molecular biology methods including Next-Generation Sequencing. We support your biochemical research by genetic testing for e.g. genotype-phenotype metabolic diseases studies or tumor biology.
Our –OMICS Plattform
We offer complete laboratory services (sample management, measurement and bioinformatics) for Small Molecule and Protein Profiling.
Contact us to learn more about our dozens of assays for amino acids and metabolic breakdown molecules, acylcarnitines and fatty acids, steroids, peptides and many more.
Biomarker Discovery
Identifying relevant biomarkers is to find a needle in a haystack. Nonetheless, biomarkers become more and more important in diagnostic applications, to help to detect or to predict diseases. Biomarkers are mandatory to move towards a more personalized medicine. Highly disease-specific biomarkers hold great promise to monitor progression of disease of patients without or under therapy.
We, at ARCHIMEDlife Research Institute, put significant effort into the discovery and testing of novel biomarkers.
ARCHIMEDlife News
-
Award for Outstanding Achievements on Rare Diseases
17 April 2025
We are very happy to share that our CEO, Dr. David C. Kasper, has been selected as the winner of the Award for Outstanding Achievements in…
-
WORLDSymposium 2025 Poster Presentations – Updates on important diagnostic services
21 February 2025
The WORLDSymposium for Lysosomal Storage Disorders convened in San Diego, CA, USA earlier this month. This important meeting brings together industry, physicians, advocate groups, and…
-
Newborn Screening and Presymptomatic Treatment of Metachromatic Leukodystrophy
23 January 2025
Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder characterized by progressive neurodegeneration due to a deficiency in the enzyme arylsulfatase-A (ARSA). This deficiency leads to…
-
MedLab Dubai. New directors appointed.
23 October 2023
New directors appointed: @Gröning, MD, as Medical Director, Dr. med. Thomas Winkler , MD and David C. Kasper (also as Manager). Our mission together with our highly experienced local…
-
In-person Conferences once again!
17 January 2022
With the start of 2022, ARCHIMEDlife is pleased to announce that we will be once again attending in-person conferences! The WORLDSymposium for lysosomal disease research…
-
The amedes group supports the NCL Foundation in Germany
07 May 2021
In January, the amedes group called on their employees to nominate charitable organizations to be supported by the amedes group in the future. The overwhelming…
About Us
"Our mission has remained clear: to provide faster, better, and more meaningful diagnostic answers — for patients, families, and physicians around the world."
What began as a pioneering laboratory for Rare Disease diagnostics has grown into a globally recognized, technology-enabled platform combining different technologies. Today, we partner with leading physicians, researchers, and pharmaceutical companies to deliver precision diagnostics at the moment they matter most.
We believe that access to high-quality, actionable health data is not just a technical challenge — it’s a human one. That’s why we are committed to developing novel, integrated tests that transform uncertainty into clarity, and delay into timely intervention.
We are accredited* and certified for:
Latest Publications
Newborn Screening and Presymptomatic Treatment of Metachromatic Leukodystrophy
23 January 2025
Metachromatic leukodystrophy (MLD) is a lysosomal storage disorder characterized by progressive neurodegeneration due to a deficiency in the enzyme arylsulfatase-A (ARSA). This deficiency leads to…
01 June 2023
Acid sphingomyelinase deficiency (ASMD), commonly called Niemann-Pick A/B disease, is an autosomal recessively inherited lysosomal storage disorder resulting from a deficiency in acid sphingomyelinase (ASM)…
In-person Conferences once again!
17 January 2022
With the start of 2022, ARCHIMEDlife is pleased to announce that we will be once again attending in-person conferences! The WORLDSymposium for lysosomal disease research…